Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

GEN — Gen Digital

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 63.37%
Profit Margins 19.46%
Return on Equity 39.88%
Return on Assets 8.67%
Free Float 0.46B
Dividend Yield 2.04%
Short Int % Utilisation 6.25%

2.2 Growth

Metric Value
Revenue Growth 27.0%
Free Cash Flow 1.42B
EBITDA 9.5 (Ratio)
Enterprise Value 22.69B
EV/Revenue 4.54
EV/EBITDA 9.5

Revenue growth of 27.0% places the company in a high-growth category.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* -2.21%
Risk / Std Dev (Ann.)* 34.58%
1-Year Price Return* -7.73%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $28.48
52-Week Range $17.78 – $31.88
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2026 FY2025
Revenue Reported revenue $5.00B $3.94B
Net income Reported net income $973.00M $643.00M
Total assets Year-end reported balance $15.59B $15.49B
Shareholders’ equity Year-end reported balance $2.61B $2.27B
Net margin Net income ÷ revenue 19.46% 16.34%
Asset turnover Revenue ÷ total assets 0.3207x 0.2540x
Equity multiplier Total assets ÷ shareholders’ equity 5.9705x 6.8290x
ROE Net margin × asset turnover × equity multiplier 37.27% 28.34%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $5.00B
Prior annual revenue $3.94B
EBIT $2.08B
Tax rate 36.00%
NOPAT = EBIT × (1 − tax rate) $1.33B
Forecast start-growth basis 15.00%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $1.33B
Add: depreciation & amortisation $493.00M
Less: capital expenditure -$22.00M
Less/(add): working-capital cash-flow movement -$647.00M
Current unlevered FCFF $1.16B

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 15.00% $1.53B $566.95M -$25.30M -$744.05M $1.33B $1.27B
2 11.88% $1.71B $634.28M -$179.80M -$832.41M $1.33B $1.17B
3 8.75% $1.86B $689.77M -$360.28M -$905.24M $1.29B $1.04B
4 5.62% $1.97B $728.57M -$554.56M -$956.16M $1.19B $875.94M
5 2.50% $2.02B $746.79M -$746.79M -$980.07M $1.04B $702.62M

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 1.20
Cost of equity 11.32%
Pre-tax cost of debt 6.87%
WACC 9.02%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $16.29B
Implied terminal EV / EBITDA 4.18x
Terminal value as % of enterprise value 67.64%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $5.06B
Present value of terminal value $10.58B
Indicated enterprise value $15.64B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $15.64B
Less: gross interest-bearing debt $8.26B
Add: cash and equivalents $402.00M
Add: affiliate investments $0.00
Less: minority interests $0.00
Indicated common equity value $7.78B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 619,000,000.00
Share-count basis reported diluted weighted-average shares
Current market price $27.82
DCF indicative value per share $12.57
Indicative value vs. market price -54.83%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 3/4 evidenced checks
Lynch-inspired balance-and-growth checks 3/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:34:46.929083 UTC; latest reported fiscal period: 2026-03-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -26.68% -20.21%
Adjusted R² 0.12 0.15
Annualised residual volatility 32.31% 31.64%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.70 (3.68) 0.91 (4.25)
Size (SMB) 0.42 (1.63) 0.21 (0.78)
Value (HML) -0.36 (-1.62) -0.83 (-3.10)
Profitability (RMW) NM 0.09 (0.38)
Investment (CMA) NM 1.12 (2.84)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequitygeninformation-technologysystems-softwarenasdaq